ArticleJournal of ovarian research2025
C-type natriuretic peptide mitigates apoptosis in ovarian granulosa cells through the cGMP pathway independent of PKG signaling.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of Autologous Exosomes to Enhance Oocyte Maturation in Patients with Diminished Ovarian Reserve: A Prospective, Randomized Clinical Trial (Pilot Study).Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMammalian follicular development is regulated by endocrine and paracrine factors, and apoptosis of granulosa cells represents a major cause of follicular atresia. C-type natriuretic peptide (CNP), a paracrine factor in follicular fluid, maintains meiotic arrest of oocytes through activation of the NPR2-cGMP pathway. Protein kinase G (PKG) is a principal downstream effector of cGMP, but its function in granulosa cell apoptosis has not been fully characterized.
methodsBovine granulosa cells were treated with CNP, cGMP or the PKG inhibitor KT5823. Transcriptomic analysis was performed to identify differentially expressed genes and signaling pathways. The effects of CNP on apoptosis were further evaluated in mural granulosa cells, cumulus-oocyte complexes (COCs), and oocytectomized complexes (OOXs). Apoptosis was examined by TUNEL assay, and expression of apoptosis-related genes and proteins was determined by RT-qPCR and Western blotting. The influence of PKG inhibition on oocyte developmental competence was assessed during in vitro maturation (IVM).
resultsCNP treatment downregulated multiple apoptosis-related pathways, including TNF, IL-17, and NF-κB signaling. CNP reduced apoptosis in both granulosa and cumulus cells, and this effect was not affected by PKG inhibition. Overexpression of PKG increased apoptosis, suggesting a pro-apoptotic role of PKG in granulosa cells. Addition of KT5823 during IVM decreased apoptosis in cumulus cells and improved blastocyst development and ICM cell numbers in bovine and ovine oocytes.
conclusionsCNP suppresses apoptosis of granulosa cells through a PKG-independent mechanism involving transcriptional downregulation of apoptosis-related pathways. PKG appears to promote, rather than mediate, apoptosis in this system. Inhibition of PKG during IVM may improve oocyte quality and provide a useful reference for optimization of in vitro maturation systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.